Kadmon Holdings Company Profile (NASDAQ:KDMN)

About Kadmon Holdings (NASDAQ:KDMN)

Kadmon Holdings logoKadmon Holdings, Inc. is an integrated biopharmaceutical company engaged in the discovery, development and commercialization of small molecules and biologics to address disease areas of various unmet medical needs. The Company is developing product candidates in a number of indications within autoimmune and fibrotic disease, oncology and genetic diseases. Its product pipeline consists of KD025, Tesevatinib and KD034. The Company's other products include Ribasphere RibaPak, Ribasphere, Qsymia, Tetrabenazine and Valganciclovir. KD025 is an orally available, selective small molecule inhibitor of Rho-associated coiled-coil kinase 2 (ROCK2), a molecular target in multiple autoimmune, fibrotic and neurodegenerative diseases. Tesevatinib is an oral tyrosine kinase inhibitor (TKI) designed to block key molecular drivers of tumor growth, metastases and drug resistance. KD034 is the Company's portfolio of enhanced formulations of trientine hydrochloride for the treatment of Wilson's disease.

Industry, Sector and Symbol:
  • Sector: Healthcare
  • Industry: Biopharmaceuticals
  • Sub-Industry: N/A
  • Symbol: NASDAQ:KDMN
  • CUSIP: N/A
  • Web: kadmon.com/
Capitalization:
  • Market Cap: $175.24 million
  • Outstanding Shares: 51,846,000
Average Prices:
  • 50 Day Moving Avg: $2.62
  • 200 Day Moving Avg: $3.62
  • 52 Week Range: $2.25 - $11.73
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -0.85
  • P/E Growth: 0.00
Sales & Book Value:
  • Annual Revenue: $21.96 million
  • Price / Sales: 7.98
  • Book Value: ($1.13) per share
  • Price / Book: -2.99
Profitability:
  • EBIDTA: ($98,790,000.00)
  • Net Margins: -315.61%
  • Return on Assets: -107.98%
Misc:
  • Average Volume: 192,550 shs.
  • Short Ratio: 8.01
 

Frequently Asked Questions for Kadmon Holdings (NASDAQ:KDMN)

What is Kadmon Holdings' stock symbol?

Kadmon Holdings trades on the NASDAQ under the ticker symbol "KDMN."

How were Kadmon Holdings' earnings last quarter?

Kadmon Holdings Inc (NASDAQ:KDMN) posted its quarterly earnings data on Monday, May, 15th. The company reported ($0.39) EPS for the quarter, topping the Zacks' consensus estimate of ($0.52) by $0.13. The business had revenue of $5.60 million for the quarter, compared to analyst estimates of $4.25 million. The business's revenue for the quarter was down 42.3% on a year-over-year basis. View Kadmon Holdings' Earnings History.

Where is Kadmon Holdings' stock going? Where will Kadmon Holdings' stock price be in 2017?

6 brokers have issued twelve-month price objectives for Kadmon Holdings' stock. Their forecasts range from $3.25 to $25.00. On average, they expect Kadmon Holdings' share price to reach $13.54 in the next twelve months. View Analyst Ratings for Kadmon Holdings.

What are analysts saying about Kadmon Holdings stock?

Here are some recent quotes from research analysts about Kadmon Holdings stock:

  • 1. According to Zacks Investment Research, "Kadmon Holdings, Inc. is a biopharmaceutical company. It engaged in the discovery, development and commercialization of small molecules and biologics to address disease areas of significant unmet medical need. The company is developing product candidates within autoimmune and fibrotic diseases, oncology and genetic diseases. Kadmon Holdings, Inc. is headquartered in New York. " (6/20/2017)
  • 2. Citigroup Inc. analysts commented, "We believe investors could find a better de-risked entry point in the next 12–18 months with more data as we see long term upside," analyst Robyn Karnauskas wrote in a note.Related Link: "Kadmon Offers A Diverse Clinical Pipeline, And Value Optionality," H.C. Wainwright Says"While we note 40–100 percent upside if every POC trial works, the stock could trade at $3–$5/sh (50–70 percent downside) if Tesevatinib fails in cancer trials & could trade at cash ($1/sh) if KD-025 also fails due to safety," the analyst continued.Karnauskas noted that the company may face cash crunch beyond first–second quarter of 2017 and they may be at risk of going to capital markets again before majority of data readout in the second half of 2017.That said, the analyst is positive on the Tesevatinib cancer program, as it crosses the blood brain barrier."We see FV of this program at $9/sh (75 percent of our valuation) and model 35 percent probability to brain met NSCLC opportunity ($400 million peak unadjusted) and 25 percent probability to GBM opportunity ($800 million peak unadjusted)," (8/22/2016)

Who are some of Kadmon Holdings' key competitors?

When did Kadmon Holdings IPO?

(KDMN) raised $101 million in an IPO on Wednesday, July 27th 2016. The company issued 5,600,000 shares at a price of $16.00-$20.00 per share. Citigroup and Jefferies acted as the underwriters for the IPO and JMP Securities and H.C. Wainwright & Co. were co-managers.

Who owns Kadmon Holdings stock?

Kadmon Holdings' stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include Perceptive Advisors LLC (10.00%), Point72 Asset Management L.P. (1.27%), Vanguard Group Inc. (1.09%), Beach Point Capital Management LP (0.49%), JPMorgan Chase & Co. (0.44%) and AE Wealth Management LLC (0.21%). Company insiders that own Kadmon Holdings stock include Bart M Schwartz, Daniel S Loeb, Goldentree Asset Management Lp, Harlan Waksal and Konstantin Poukalov. View Institutional Ownership Trends for Kadmon Holdings.

Who sold Kadmon Holdings stock? Who is selling Kadmon Holdings stock?

Kadmon Holdings' stock was sold by a variety of institutional investors in the last quarter, including Point72 Asset Management L.P.. View Insider Buying and Selling for Kadmon Holdings.

Who bought Kadmon Holdings stock? Who is buying Kadmon Holdings stock?

Kadmon Holdings' stock was bought by a variety of institutional investors in the last quarter, including Perceptive Advisors LLC, Vanguard Group Inc., JPMorgan Chase & Co., AE Wealth Management LLC, Nationwide Fund Advisors, Renaissance Technologies LLC, Bank of New York Mellon Corp and KCG Holdings Inc.. Company insiders that have bought Kadmon Holdings stock in the last two years include Bart M Schwartz, Daniel S Loeb, Goldentree Asset Management Lp, Harlan Waksal and Konstantin Poukalov. View Insider Buying and Selling for Kadmon Holdings.

How do I buy Kadmon Holdings stock?

Shares of Kadmon Holdings can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Kadmon Holdings' stock price today?

One share of Kadmon Holdings stock can currently be purchased for approximately $3.38.


MarketBeat Community Rating for Kadmon Holdings (NASDAQ KDMN)
Community Ranking:  3.0 out of 5 (  )
Outperform Votes:  35 (Vote Outperform)
Underperform Votes:  23 (Vote Underperform)
Total Votes:  58
MarketBeat's community ratings are surveys of what our community members think about Kadmon Holdings and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Kadmon Holdings (NASDAQ:KDMN) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 2 Hold Ratings, 4 Buy Ratings
Consensus Rating:Buy (Score: 2.67)
Consensus Price Target: $13.54 (300.64% upside)

Analysts' Ratings History for Kadmon Holdings (NASDAQ:KDMN)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
3/27/2017Citigroup Inc.Lower Price TargetNeutral$6.00 -> $4.00HighView Rating Details
3/23/2017Piper Jaffray CompaniesReiterated RatingOverweight$36.10 -> $23.00LowView Rating Details
3/16/2017WBB SecuritiesUpgradeSell -> Hold$3.25MediumView Rating Details
2/1/2017HC WainwrightReiterated RatingBuy$25.00N/AView Rating Details
11/21/2016JMP SecuritiesReiterated RatingBuyN/AView Rating Details
11/10/2016Jefferies Group LLCReiterated RatingBuy$12.00 -> $10.00N/AView Rating Details
(Data available from 6/24/2015 forward)

Earnings

Earnings History for Kadmon Holdings (NASDAQ:KDMN)
Earnings by Quarter for Kadmon Holdings (NASDAQ:KDMN)
Earnings History by Quarter for Kadmon Holdings (NASDAQ KDMN)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/15/2017Q1 2017($0.52)($0.39)$4.25 million$5.60 millionViewN/AView Earnings Details
3/22/2017Q4 2016($0.71)($0.50)$4.50 million$4.28 millionViewN/AView Earnings Details
11/9/2016Q3 2016($0.40)($4.23)$3.90 million$5.70 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Kadmon Holdings (NASDAQ:KDMN)
2017 EPS Consensus Estimate: ($1.83)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20171($0.49)($0.49)($0.49)
Q2 20171($0.53)($0.53)($0.53)
Q3 20171($0.45)($0.45)($0.45)
Q4 20171($0.36)($0.36)($0.36)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Kadmon Holdings (NASDAQ:KDMN)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Kadmon Holdings (NASDAQ:KDMN)
Insider Trades by Quarter for Kadmon Holdings (NASDAQ:KDMN)
Institutional Ownership by Quarter for Kadmon Holdings (NASDAQ:KDMN)
Insider Trades by Quarter for Kadmon Holdings (NASDAQ:KDMN)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
3/13/2017Daniel S LoebMajor ShareholderBuy1,488,095$3.36$4,999,999.20View SEC Filing  
11/16/2016Harlan WaksalCEOBuy2,000$6.37$12,740.00View SEC Filing  
11/14/2016Harlan WaksalCEOBuy2,000$6.79$13,580.00View SEC Filing  
11/11/2016Konstantin PoukalovCFOBuy4,000$5.81$23,240.00View SEC Filing  
9/14/2016Daniel S LoebMajor ShareholderBuy19,611$7.79$152,769.69View SEC Filing  
9/13/2016Daniel S LoebMajor ShareholderBuy68,654$8.33$571,887.82View SEC Filing  
9/6/2016Daniel S LoebMajor ShareholderBuy81,781$9.39$767,923.59View SEC Filing  
8/26/2016Daniel S LoebMajor ShareholderBuy32,916$9.98$328,501.68View SEC Filing  
8/22/2016Daniel S LoebMajor ShareholderBuy11,305$10.00$113,050.00View SEC Filing  
8/15/2016Daniel S LoebMajor ShareholderBuy6,010$9.95$59,799.50View SEC Filing  
8/12/2016Daniel S LoebMajor ShareholderBuy87,529$9.98$873,539.42View SEC Filing  
8/5/2016Daniel S LoebMajor ShareholderBuy66,828$9.94$664,270.32View SEC Filing  
8/3/2016Daniel S LoebMajor ShareholderBuy1,431,996$11.35$16,253,154.60View SEC Filing  
8/1/2016Goldentree Asset Management LpMajor ShareholderBuy208,333$12.00$2,499,996.00View SEC Filing  
7/28/2016Bart M SchwartzDirectorBuy2,000$9.77$19,540.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Kadmon Holdings (NASDAQ:KDMN)
Latest Headlines for Kadmon Holdings (NASDAQ:KDMN)
Source:
DateHeadline
streetinsider.com logoKadmon (KDMN) to Present Interim Data on KD025 in cGVHD at R&D Day
www.streetinsider.com - June 24 at 4:31 AM
finance.yahoo.com logoKadmon to Present Interim Data on KD025 in Chronic Graft-Versus-Host Disease (cGVHD) at R&D Day
finance.yahoo.com - June 23 at 6:30 PM
finance.yahoo.com logoETFs with exposure to Kadmon Holdings, Inc. : June 22, 2017
finance.yahoo.com - June 23 at 6:55 AM
nasdaq.com logoBUZZ-US STOCKS ON THE MOVE-Red Hat, CA Inc, AMD, Foot Locker, Signet, La-Z-Boy, Chuy's - Nasdaq
www.nasdaq.com - June 21 at 3:54 PM
americanbankingnews.com logoKadmon Holdings Inc (KDMN) Receives Consensus Rating of "Buy" from Brokerages
www.americanbankingnews.com - June 20 at 8:54 PM
finance.yahoo.com logoETFs with exposure to Kadmon Holdings, Inc. : June 5, 2017
finance.yahoo.com - June 5 at 6:51 PM
finance.yahoo.com logoKadmon to Present at the Jefferies 2017 Global Healthcare Conference
finance.yahoo.com - June 5 at 10:02 AM
finance.yahoo.com logoKadmon Holdings, Inc. :KDMN-US: Earnings Analysis: Q1, 2017 By the Numbers : June 2, 2017
finance.yahoo.com - June 2 at 7:32 PM
streetinsider.com logoKadmon (KDMN) Says Data Shows Potential of New GLUT Inhibitors for Treatment of Autoimmune and Inflammatory Conditions
www.streetinsider.com - June 1 at 6:57 PM
streetinsider.com logoKadmon (KDMN) Says Data Shows Potential of New GLUT ... - StreetInsider.com
www.streetinsider.com - June 1 at 6:57 PM
finance.yahoo.com logoKadmon Announces Data Demonstrating the Potential of the Company’s New GLUT Inhibitors for the Treatment of Autoimmune and Inflammatory Conditions
finance.yahoo.com - June 1 at 6:57 PM
americanbankingnews.com logoKadmon Holdings Inc (KDMN) Given Consensus Rating of "Buy" by Analysts
www.americanbankingnews.com - May 26 at 9:04 PM
businesswire.com logoRobbins Arroyo LLP Is Investigating the Officers and Directors of Kadmon Holdings, Inc. (KDMN) on Behalf of ... - Business Wire (press release)
www.businesswire.com - May 24 at 11:18 AM
americanbankingnews.com logoKadmon Holdings Inc (KDMN) Rating Lowered to Hold at Zacks Investment Research
www.americanbankingnews.com - May 23 at 11:48 PM
finance.yahoo.com logoRobbins Arroyo LLP Is Investigating the Officers and Directors of Kadmon Holdings, Inc. (KDMN) on Behalf of Shareholders
finance.yahoo.com - May 22 at 5:33 PM
finance.yahoo.com logoScott+Scott, Attorneys at Law, LLP Announces Investigation of Kadmon Holdings Inc. (KDMN)
finance.yahoo.com - May 16 at 5:59 PM
americanbankingnews.com logoKadmon Holdings Inc (KDMN) Releases Quarterly Earnings Results, Beats Expectations By $0.13 EPS
www.americanbankingnews.com - May 15 at 2:16 PM
finance.yahoo.com logoKadmon Provides Business Update and Reports First Quarter 2017 Financial Results
finance.yahoo.com - May 15 at 10:44 AM
reuters.com logoBRIEF-Kadmon Holdings says CEO Harlan Waksal's total compensation for 2016 was $13.4 mln vs$16.3 mln in 2015 - SEC filing
www.reuters.com - May 11 at 11:42 PM
finance.yahoo.com logoKadmon to Present Clinical and Preclinical Data Highlighting the Role of ROCK2 Signaling in Immune System Function at AAI Annual Meeting
finance.yahoo.com - May 11 at 6:38 PM
finance.yahoo.com logoKadmon Announces Publication of Clinical Data Showing KD025 Improved Clinical Scores in Psoriasis Patients
finance.yahoo.com - April 12 at 7:03 PM
finance.yahoo.com logoKadmon Submits Second Abbreviated New Drug Application Filing for Trientine Hydrochloride to FDA
finance.yahoo.com - April 7 at 10:40 AM
americanbankingnews.com logoKadmon Holdings Inc (KDMN) Receives Average Recommendation of "Buy" from Analysts
www.americanbankingnews.com - April 4 at 6:10 PM
finance.yahoo.com logoKadmon Announces Amendment to Credit Agreement and Related Warrants
finance.yahoo.com - April 4 at 6:03 AM
biz.yahoo.com logoKADMON HOLDINGS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Creation of a Direct Financial
biz.yahoo.com - April 4 at 6:03 AM
americanbankingnews.com logoKadmon Holdings Inc (KDMN) Rating Increased to Buy at Zacks Investment Research
www.americanbankingnews.com - April 1 at 3:30 PM
finance.yahoo.com logoKADMON HOLDINGS, INC. Financials
finance.yahoo.com - March 28 at 5:44 PM
streetinsider.com logoKadmon (KDMN) Presents Preclinical Data Supporting Therapeutic Potential of ROCK Inhibition in Pulmonary Fibrosis
www.streetinsider.com - March 28 at 10:57 AM
us.rd.yahoo.com logoKadmon Presents Preclinical Data Supporting the Therapeutic Potential of ROCK Inhibition in Pulmonary Fibrosis
us.rd.yahoo.com - March 28 at 10:57 AM
americanbankingnews.com logoKadmon Holdings Inc (KDMN) Price Target Lowered to $4.00 at Citigroup Inc
www.americanbankingnews.com - March 27 at 9:20 AM
americanbankingnews.com logoQ1 2017 Earnings Forecast for Kadmon Holdings Inc (KDMN) Issued By Jefferies Group
www.americanbankingnews.com - March 27 at 8:14 AM
americanbankingnews.com logoKadmon Holdings Inc to Post FY2021 Earnings of ($0.66) Per Share, Jefferies Group Forecasts (KDMN)
www.americanbankingnews.com - March 24 at 2:28 PM
americanbankingnews.com logoKadmon Holdings Inc (KDMN) Given Overweight Rating at Piper Jaffray Companies
www.americanbankingnews.com - March 23 at 5:10 PM
uk.finance.yahoo.com logoKadmon Reports Upcoming Milestones and Fourth Quarter and Full Year 2016 Financial Results
us.rd.yahoo.com - March 22 at 6:20 PM
americanbankingnews.com logoKadmon Holdings Inc (KDMN) Rating Increased to Hold at WBB Securities
www.americanbankingnews.com - March 22 at 10:38 AM
bloomberg.com logoBloomberg Markets: Dave Wilson’s Stock of the Day for March 20
www.bloomberg.com - March 21 at 12:11 PM
us.rd.yahoo.com logoCoverage initiated on Kadmon Holdings by Piper Jaffray
us.rd.yahoo.com - March 14 at 5:19 PM
biz.yahoo.com logoKADMON HOLDINGS, INC. Files SEC form 8-K/A, Entry into a Material Definitive Agreement, Unregistered Sale of Equity S
biz.yahoo.com - March 9 at 8:25 AM
us.rd.yahoo.com logoKadmon Announces Approximately $23 Million Equity Financing
us.rd.yahoo.com - March 8 at 6:53 PM
streetinsider.com logoKadmon (KDMN) Issues Encouraging Update on Tesevatinib Phase 2 in NSCLC - StreetInsider.com
www.streetinsider.com - December 8 at 10:21 AM
streetinsider.com logoKadmon (KDMN) Issues Encouraging Update on Tesevatinib Phase 2 in NSCLC
www.streetinsider.com - December 7 at 10:28 AM
streetinsider.com logoKadmon (KDMN) Submits ANDA for KD034
www.streetinsider.com - December 6 at 10:23 AM
us.rd.yahoo.com logoKadmon Presents Encouraging Data on Tesevatinib in EGFR-Mutated Non-Small Cell Lung Cancer with Brain Metastases and/or Leptomeningeal Metastases
us.rd.yahoo.com - December 6 at 10:23 AM
us.rd.yahoo.com logo8:31 am Kadmon Holdings announces data from its ongoing Phase 2 clinical study of tesevatinib for the treatment of epidermal growth factor receptor NSCLC that has metastasized to the brain and/or the leptomeninges
us.rd.yahoo.com - December 6 at 10:23 AM
businesswire.com logoKadmon Submits Abbreviated New Drug Application Filing for Trientine Hydrochloride to FDA - Business Wire (press release)
www.businesswire.com - December 5 at 6:22 PM
finance.yahoo.com logo4:01 pm Kadmon Holdings submits ANDA for KD034 - first application submitted to the FDA for a generic trientine hydrochloride product for the treatment of Wilson's disease
finance.yahoo.com - December 5 at 6:22 PM
finance.yahoo.com logoKadmon Submits Abbreviated New Drug Application Filing for Trientine Hydrochloride to FDA
finance.yahoo.com - December 5 at 6:22 PM
finance.yahoo.com logoKadmon to Present at the 28th Annual Piper Jaffray Healthcare Conference
finance.yahoo.com - November 29 at 4:20 PM
businesswire.com logoKadmon to Present Additional Data Demonstrating Tesevatinib Safety for the Treatment of Polycystic Kidney Disease at ... - Business Wire (press release)
www.businesswire.com - November 21 at 10:56 AM
streetinsider.com logoForm 424B3 Kadmon Holdings, Inc. - StreetInsider.com
www.streetinsider.com - November 21 at 10:56 AM

Social

Chart

Kadmon Holdings (KDMN) Chart for Saturday, June, 24, 2017

This page was last updated on 6/24/2017 by MarketBeat.com Staff